Evidence For Activity Of GBR 830 (Anti-OX40) In Extrinsic And Intrinsic Atopic Dermatitis (AD) In A Phase 2A Study
Evidence For Activity Of GBR 830 (Anti-OX40) In Extrinsic And Intrinsic Atopic Dermatitis (AD) In A Phase 2A Study
GBR 830, An Anti-OX40, Improves Skin Gene Signatures And Clinical Scores In Patients With Atopic Dermatitis
Clinical Pharmokinetics And Immunogenicity Of GBR 830, A First-In-Class Humanized Monoclonal Antibody Inhibiting OX40 To Treat Atopic Dermatitis
GBR 830 Induces Progressive And Sustained Improvements In Atopic Dermatitis Skin Biomarkers And Clinical Parameters
Clinical Pharmacokinetics And Immunogenicity Of GBR 830, A First-In-Class Humanized Monoclonal Antibody Inhibiting OX40 To Treat Atopic Dermatitis
GBR 830 Induces Progressive And Sustained Improvements In Atopic Dermatitis Skin Biomarkers And Clinical Parameters
Results From A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
Results From A Randomized, Double-Blind, Placebo‐Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
